1. Are we failing in treatment of adrenocortical carcinoma? Lights and shadows of molecular signatures
- Author
-
Alfredo Berruti, Salvatore Grisanti, Sandra Sigala, Elisa Rossini, Andrea Abate, Marta Laganà, and Deborah Cosentini
- Subjects
0301 basic medicine ,business.industry ,Endocrinology, Diabetes and Metabolism ,Preclinical pharmacology ,030209 endocrinology & metabolism ,Disease ,adrenocortical cancer genomic ,Bioinformatics ,medicine.disease ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Cancer genome ,Medicine ,Adrenocortical carcinoma ,business ,Functional genomics ,Rare disease - Abstract
Adrenocortical carcinoma (ACC) is a rare disease whose prognosis is reported to be invariably poor mainly because of lack of effective and durable treatments, which makes this cancer an orphan disease. Recent studies of functional genomics and, in particular, the results from The Cancer Genome Atlas (TCGA) project have shed new light on the molecular biology of ACC while improving our comprehension of potentially targetable alterations. This review is focused on the shift of methodology in preclinical pharmacology and drug selection for patients with ACC which is rapidly moving from a heuristic approach to a dynamic, deterministic one.
- Published
- 2019
- Full Text
- View/download PDF